Introduction

If you are managing joint pain from wear or localised cartilage damage, one practical question is whether the ChondroFiller injection could help — and, if so, whether you are likely to be a suitable candidate. This article sets out what the procedure involves, who it tends to suit, and what realistic expectations look like.

What Is the ChondroFiller Injection?

ChondroFiller is a Class III CE-marked medical device: an acellular, in-situ gelling scaffold composed of type I collagen, made by Meidrix Biomedicals and imported into the UK under prescription. When delivered as an injection, it is placed into the joint through a fine needle under ultrasound guidance in an outpatient setting — no theatre, no incision, no general anaesthetic is required.

Once inside the joint, the collagen solution gels within a few minutes, settling over the worn surface to form a stable, biocompatible matrix. The scaffold is gradually replaced by the patient's own progenitor cells, which are recruited from the surrounding tissue. Over time this may support cartilage repair, though this is a biologically variable process and outcomes differ between individuals.

It is important to understand what ChondroFiller is not: it is not a filler that will permanently cushion the joint, nor a cure for arthritis. It is a regenerative support for localised cartilage defects in joints that are otherwise reasonably well preserved.

ChondroFiller Injection vs Liquid Cartilage — Two Different Pathways

Patients sometimes encounter both terms and find them confusing. ChondroFiller is the device (the collagen scaffold). The ChondroFiller injection is the non-surgical delivery pathway described in this article. Liquid Cartilage — properly the Lee Liquid Cartilage Protocol — is a separate, keyhole surgical procedure developed by Professor Paul Y. F. Lee in which the ChondroFiller scaffold is placed arthroscopically into the joint alongside biological adjuncts and, where indicated, the patient's own mesenchymal stem cells. Liquid Cartilage is used for larger or load-bearing defects and is genuine surgery requiring theatre and anaesthetic.

If your assessment suggests a larger defect, a heavily load-bearing joint, or a lesion that is difficult to reach by simple injection, the surgical Liquid Cartilage route is likely to be discussed instead of, or as well as, the injection.

Who May Be Suitable for the Injection?

There is no single threshold that determines suitability — it is established by clinical examination, symptom history, and imaging, usually MRI. That said, the characteristics that tend to support consideration of the ChondroFiller injection include:

• Localised cartilage wear or a focal cartilage defect (rather than advanced, widespread joint disease)
• Osteoarthritis or joint wear that is causing meaningful symptoms — pain, stiffness, or reduced function — that has not been adequately managed by physiotherapy or other conservative measures
• A joint that is otherwise mechanically sound: good alignment, stable ligaments, and without significant bone loss or deformity
• Absence of severe end-stage arthritis, in which the remaining joint space is too compromised for a regenerative scaffold to be effective
• General fitness for any injection procedure, including no active joint infection and no relevant contraindication to the device material

Age alone is not a bar to consideration. People across a range of ages have received the injection, although the biological response — and therefore the likely benefit — tends to be more robust in joints where some cartilage quality remains and where the patient's healing capacity is not significantly impaired.

Corain and colleagues (2023) reported on use of the acellular collagen scaffold in trapeziometacarpal osteoarthritis, demonstrating meaningful pain reduction and functional improvement, illustrating that the application is not limited to the knee.

Who Is Less Likely to Benefit?

The injection is less likely to be appropriate, or may not be recommended, in the following situations:

• Advanced or end-stage arthritis with significant loss of joint space across the whole joint
• Significant malalignment or instability that has not been corrected — these mechanical factors reduce the likelihood of a good outcome regardless of the biological treatment
• Active infection in or near the joint
• Systemic inflammatory joint disease in an active flare, where the joint environment may not support regeneration
• Very large defects better suited to the surgical Liquid Cartilage protocol

People who fall outside the injection criteria are not without options. Depending on the joint, defect size, and overall clinical picture, the surgical Liquid Cartilage protocol, other biologics, or joint-preservation surgery may be more appropriate and would be discussed at assessment.

What to Expect

The process begins with a consultation to review symptoms, examine the joint, and assess imaging. If the ChondroFiller injection is felt to be suitable, it is performed as an outpatient procedure under ultrasound guidance. Recovery is typically straightforward: most people return to normal activities promptly, with physiotherapy recommended to support joint loading and movement in the weeks following.

Benefits, if they occur, tend to develop gradually over the months following the injection as the scaffold supports tissue repair. Some people notice improvement within a few weeks; for others the response takes longer. A proportion do not experience a significant benefit — suitability assessment reduces this risk but cannot eliminate it.

Conclusion

Careful patient selection is central to obtaining worthwhile results from the ChondroFiller injection. The procedure is suited to people with localised joint wear in an otherwise mechanically sound joint, where conservative management has not been sufficient. It is not a cure for arthritis and does not replace the need for good joint mechanics and rehabilitation.

At the London Cartilage Clinic, assessment covers both injection and surgical pathways, so that patients receive the option most likely to suit their specific joint, defect, and clinical circumstances. For individual advice, a consultation with a qualified specialist is the appropriate first step.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.